#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Recent World Health Organization ( WHO ) evidence reviews , published in the International Journal of Environmental Research and Public Health , have revealed sufficient evidence that sources of transportation noise lead to serious annoyance , sleep disturbance , and cardio-metabolic disorders .
3-1	17-23	Recent	organization[4]	new[4]	_	_
3-2	24-29	World	organization[4]	new[4]	_	_
3-3	30-36	Health	abstract|organization[4]	new|new[4]	coref	3-20[9_0]
3-4	37-49	Organization	organization[4]	new[4]	_	_
3-5	50-51	(	abstract[6]	new[6]	coref	19-11[152_6]
3-6	52-55	WHO	abstract[6]	new[6]	_	_
3-7	56-57	)	abstract[6]	new[6]	_	_
3-8	58-66	evidence	abstract|abstract[6]	new|new[6]	coref	3-25[10_0]
3-9	67-74	reviews	abstract[6]	new[6]	_	_
3-10	75-76	,	_	_	_	_
3-11	77-86	published	_	_	_	_
3-12	87-89	in	_	_	_	_
3-13	90-93	the	organization[7]	new[7]	_	_
3-14	94-107	International	organization[7]	new[7]	_	_
3-15	108-115	Journal	organization[7]	new[7]	_	_
3-16	116-118	of	organization[7]	new[7]	_	_
3-17	119-132	Environmental	organization[7]|organization[8]	new[7]|new[8]	_	_
3-18	133-141	Research	organization[7]|organization[8]	new[7]|new[8]	_	_
3-19	142-145	and	organization[7]	new[7]	_	_
3-20	146-152	Public	organization[7]|abstract[9]	new[7]|giv[9]	coref	4-11[20_9]
3-21	153-159	Health	organization[7]|abstract[9]	new[7]|giv[9]	_	_
3-22	160-161	,	_	_	_	_
3-23	162-166	have	_	_	_	_
3-24	167-175	revealed	_	_	_	_
3-25	176-186	sufficient	abstract[10]	giv[10]	coref	4-3[0_10]
3-26	187-195	evidence	abstract[10]	giv[10]	_	_
3-27	196-200	that	_	_	_	_
3-28	201-208	sources	abstract[11]	new[11]	_	_
3-29	209-211	of	abstract[11]	new[11]	_	_
3-30	212-226	transportation	abstract[11]|abstract|abstract[13]	new[11]|new|new[13]	coref|coref	18-19[146_13]|18-19[146_13]
3-31	227-232	noise	abstract[11]|abstract[13]	new[11]|new[13]	_	_
3-32	233-237	lead	_	_	_	_
3-33	238-240	to	_	_	_	_
3-34	241-248	serious	abstract[14]	new[14]	_	_
3-35	249-258	annoyance	abstract[14]	new[14]	_	_
3-36	259-260	,	_	_	_	_
3-37	261-266	sleep	abstract|abstract[16]	new|new[16]	_	_
3-38	267-278	disturbance	abstract[16]	new[16]	_	_
3-39	279-280	,	_	_	_	_
3-40	281-284	and	_	_	_	_
3-41	285-301	cardio-metabolic	abstract[17]	new[17]	coref	6-6[32_17]
3-42	302-311	disorders	abstract[17]	new[17]	_	_
3-43	312-313	.	_	_	_	_

#Text=Less convincing evidence and no exposure-response information was provided for mental health .
4-1	314-318	Less	_	_	_	_
4-2	319-329	convincing	_	_	_	_
4-3	330-338	evidence	abstract	giv	coref	11-7
4-4	339-342	and	_	_	_	_
4-5	343-345	no	abstract[19]	new[19]	_	_
4-6	346-363	exposure-response	abstract[19]	new[19]	_	_
4-7	364-375	information	abstract[19]	new[19]	_	_
4-8	376-379	was	_	_	_	_
4-9	380-388	provided	_	_	_	_
4-10	389-392	for	_	_	_	_
4-11	393-399	mental	abstract[20]	giv[20]	coref	5-1[21_20]
4-12	400-406	health	abstract[20]	giv[20]	_	_
4-13	407-408	.	_	_	_	_

#Text=Mental health is a perquisite for well-being and participation in social and economic life , with the burden already amounting to about 4 % of the gross domestic product across European Union countries .
5-1	409-415	Mental	abstract[21]	giv[21]	coref	5-4[22_21]
5-2	416-422	health	abstract[21]	giv[21]	_	_
5-3	423-425	is	_	_	_	_
5-4	426-427	a	abstract[22]	giv[22]	coref	8-31[0_22]
5-5	428-438	perquisite	abstract[22]	giv[22]	_	_
5-6	439-442	for	abstract[22]	giv[22]	_	_
5-7	443-453	well-being	abstract[22]|abstract	giv[22]|new	_	_
5-8	454-457	and	abstract[22]	giv[22]	_	_
5-9	458-471	participation	abstract[22]|abstract[24]	giv[22]|new[24]	_	_
5-10	472-474	in	abstract[22]|abstract[24]	giv[22]|new[24]	_	_
5-11	475-481	social	abstract[22]|abstract[24]|abstract[25]	giv[22]|new[24]|new[25]	coref	11-32[81_25]
5-12	482-485	and	abstract[22]|abstract[24]|abstract[25]	giv[22]|new[24]|new[25]	_	_
5-13	486-494	economic	abstract[22]|abstract[24]|abstract[25]	giv[22]|new[24]|new[25]	_	_
5-14	495-499	life	abstract[22]|abstract[24]|abstract[25]	giv[22]|new[24]|new[25]	_	_
5-15	500-501	,	abstract[22]	giv[22]	_	_
5-16	502-506	with	abstract[22]	giv[22]	_	_
5-17	507-510	the	abstract[22]|abstract[26]	giv[22]|new[26]	coref	14-10[110_26]
5-18	511-517	burden	abstract[22]|abstract[26]	giv[22]|new[26]	_	_
5-19	518-525	already	_	_	_	_
5-20	526-535	amounting	_	_	_	_
5-21	536-538	to	_	_	_	_
5-22	539-544	about	quantity[27]	new[27]	_	_
5-23	545-546	4	quantity[27]	new[27]	_	_
5-24	547-548	%	quantity[27]	new[27]	_	_
5-25	549-551	of	quantity[27]	new[27]	_	_
5-26	552-555	the	quantity[27]|abstract[28]	new[27]|new[28]	_	_
5-27	556-561	gross	quantity[27]|abstract[28]	new[27]|new[28]	_	_
5-28	562-570	domestic	quantity[27]|abstract[28]	new[27]|new[28]	_	_
5-29	571-578	product	quantity[27]|abstract[28]	new[27]|new[28]	_	_
5-30	579-585	across	quantity[27]|abstract[28]	new[27]|new[28]	_	_
5-31	586-594	European	quantity[27]|abstract[28]|place[29]|place[30]	new[27]|new[28]|new[29]|new[30]	coref|coref	8-11[47_30]|8-11[47_30]
5-32	595-600	Union	quantity[27]|abstract[28]|place[29]|place[30]	new[27]|new[28]|new[29]|new[30]	_	_
5-33	601-610	countries	quantity[27]|abstract[28]|place[30]	new[27]|new[28]|new[30]	_	_
5-34	611-612	.	_	_	_	_

#Text=Unlike other chronic diseases , mental disorders such as anxiety and depression show an early-life onset , ranging from mild and time-limited to chronic and severe impairments .
6-1	613-619	Unlike	_	_	_	_
6-2	620-625	other	abstract[31]	new[31]	_	_
6-3	626-633	chronic	abstract[31]	new[31]	_	_
6-4	634-642	diseases	abstract[31]	new[31]	_	_
6-5	643-644	,	_	_	_	_
6-6	645-651	mental	abstract[32]	giv[32]	coref	8-8[46_32]
6-7	652-661	disorders	abstract[32]	giv[32]	_	_
6-8	662-666	such	abstract[32]	giv[32]	_	_
6-9	667-669	as	abstract[32]	giv[32]	_	_
6-10	670-677	anxiety	abstract[32]|abstract|abstract[34]	giv[32]|new|new[34]	coref|coref|coref|coref	8-6|8-6[44_34]|8-6|8-6[44_34]
6-11	678-681	and	abstract[32]|abstract[34]	giv[32]|new[34]	_	_
6-12	682-692	depression	abstract[32]|abstract[34]|abstract	giv[32]|new[34]|new	coref	11-37
6-13	693-697	show	_	_	_	_
6-14	698-700	an	event[36]	new[36]	ana	8-26[0_36]
6-15	701-711	early-life	event[36]	new[36]	_	_
6-16	712-717	onset	event[36]	new[36]	_	_
6-17	718-719	,	_	_	_	_
6-18	720-727	ranging	_	_	_	_
6-19	728-732	from	_	_	_	_
6-20	733-737	mild	_	_	_	_
6-21	738-741	and	_	_	_	_
6-22	742-754	time-limited	_	_	_	_
6-23	755-757	to	_	_	_	_
6-24	758-765	chronic	abstract[37]	new[37]	_	_
6-25	766-769	and	abstract[37]	new[37]	_	_
6-26	770-776	severe	abstract[37]	new[37]	_	_
6-27	777-788	impairments	abstract[37]	new[37]	_	_
6-28	789-790	.	_	_	_	_

#Text=This feature makes the illness difficult to identify , and therefore , it is often poorly treated and overlooked .
7-1	791-795	This	abstract[38]	new[38]	_	_
7-2	796-803	feature	abstract[38]	new[38]	_	_
7-3	804-809	makes	_	_	_	_
7-4	810-813	the	abstract[39]	new[39]	ana	7-13[0_39]
7-5	814-821	illness	abstract[39]	new[39]	_	_
7-6	822-831	difficult	abstract[39]	new[39]	_	_
7-7	832-834	to	abstract[39]	new[39]	_	_
7-8	835-843	identify	abstract[39]	new[39]	_	_
7-9	844-845	,	_	_	_	_
7-10	846-849	and	_	_	_	_
7-11	850-859	therefore	_	_	_	_
7-12	860-861	,	_	_	_	_
7-13	862-864	it	abstract	giv	_	_
7-14	865-867	is	_	_	_	_
7-15	868-873	often	_	_	_	_
7-16	874-880	poorly	_	_	_	_
7-17	881-888	treated	_	_	_	_
7-18	889-892	and	_	_	_	_
7-19	893-903	overlooked	_	_	_	_
7-20	904-905	.	_	_	_	_

#Text=The 12-month point prevalence of anxiety and depressive disorders in Western countries sums up to 10 % – 14 % on average now , and it has become a public health priority issue around the World in the case of adults and children .
8-1	906-909	The	abstract[42]	new[42]	coref	10-37[70_42]
8-2	910-918	12-month	abstract[42]	new[42]	_	_
8-3	919-924	point	abstract|abstract[42]	new|new[42]	_	_
8-4	925-935	prevalence	abstract[42]	new[42]	_	_
8-5	936-938	of	abstract[42]	new[42]	_	_
8-6	939-946	anxiety	abstract[42]|abstract|abstract[44]	new[42]|giv|giv[44]	coref|coref	11-39|11-39
8-7	947-950	and	abstract[42]|abstract[44]	new[42]|giv[44]	_	_
8-8	951-961	depressive	abstract[42]|abstract[44]|abstract|abstract[46]	new[42]|giv[44]|new|giv[46]	coref|coref	10-6[63_46]|10-6[63_46]
8-9	962-971	disorders	abstract[42]|abstract[44]|abstract[46]	new[42]|giv[44]|giv[46]	_	_
8-10	972-974	in	abstract[42]|abstract[44]|abstract[46]	new[42]|giv[44]|giv[46]	_	_
8-11	975-982	Western	abstract[42]|abstract[44]|abstract[46]|place[47]	new[42]|giv[44]|giv[46]|giv[47]	_	_
8-12	983-992	countries	abstract[42]|abstract[44]|abstract[46]|place[47]	new[42]|giv[44]|giv[46]|giv[47]	_	_
8-13	993-997	sums	_	_	_	_
8-14	998-1000	up	_	_	_	_
8-15	1001-1003	to	_	_	_	_
8-16	1004-1006	10	quantity[48]	new[48]	_	_
8-17	1007-1008	%	quantity[48]	new[48]	_	_
8-18	1009-1010	–	quantity[48]	new[48]	_	_
8-19	1011-1013	14	quantity[48]|quantity[49]	new[48]|new[49]	_	_
8-20	1014-1015	%	quantity[48]|quantity[49]	new[48]|new[49]	_	_
8-21	1016-1018	on	quantity[48]|quantity[49]	new[48]|new[49]	_	_
8-22	1019-1026	average	quantity[48]|quantity[49]	new[48]|new[49]	_	_
8-23	1027-1030	now	quantity[48]|quantity[49]	new[48]|new[49]	_	_
8-24	1031-1032	,	_	_	_	_
8-25	1033-1036	and	_	_	_	_
8-26	1037-1039	it	event	giv	_	_
8-27	1040-1043	has	_	_	_	_
8-28	1044-1050	become	_	_	_	_
8-29	1051-1052	a	_	_	_	_
8-30	1053-1059	public	_	_	_	_
8-31	1060-1066	health	abstract	giv	coref	11-10[74_0]
8-32	1067-1075	priority	abstract	new	_	_
8-33	1076-1081	issue	_	_	_	_
8-34	1082-1088	around	_	_	_	_
8-35	1089-1092	the	place[53]	new[53]	_	_
8-36	1093-1098	World	place[53]	new[53]	_	_
8-37	1099-1101	in	_	_	_	_
8-38	1102-1105	the	abstract[54]	new[54]	_	_
8-39	1106-1110	case	abstract[54]	new[54]	_	_
8-40	1111-1113	of	abstract[54]	new[54]	_	_
8-41	1114-1120	adults	abstract[54]|person	new[54]|new	_	_
8-42	1121-1124	and	abstract[54]	new[54]	_	_
8-43	1125-1133	children	abstract[54]|person	new[54]|new	_	_
8-44	1134-1135	.	_	_	_	_

#Text=Although the treatment of both conditions is increasing , undertreatment is still prevalent and treatment effectiveness is modest .
9-1	1136-1144	Although	_	_	_	_
9-2	1145-1148	the	abstract[57]	new[57]	coref	9-15[0_57]
9-3	1149-1158	treatment	abstract[57]	new[57]	_	_
9-4	1159-1161	of	abstract[57]	new[57]	_	_
9-5	1162-1166	both	abstract[57]|abstract[58]	new[57]|new[58]	_	_
9-6	1167-1177	conditions	abstract[57]|abstract[58]	new[57]|new[58]	_	_
9-7	1178-1180	is	_	_	_	_
9-8	1181-1191	increasing	_	_	_	_
9-9	1192-1193	,	_	_	_	_
9-10	1194-1208	undertreatment	abstract	new	_	_
9-11	1209-1211	is	_	_	_	_
9-12	1212-1217	still	_	_	_	_
9-13	1218-1227	prevalent	_	_	_	_
9-14	1228-1231	and	_	_	_	_
9-15	1232-1241	treatment	abstract|abstract[61]	giv|new[61]	coref|coref	10-18[65_0]|10-18[65_0]
9-16	1242-1255	effectiveness	abstract[61]	new[61]	_	_
9-17	1256-1258	is	_	_	_	_
9-18	1259-1265	modest	_	_	_	_
9-19	1266-1267	.	_	_	_	_

#Text=Moreover , the pathway to mental disorders is a complex and interactive process , and over-reliance on individual treatment at the expense of broader “ structural prevention ” approaches has further hindered the successful reduction of disease prevalence .
10-1	1268-1276	Moreover	_	_	_	_
10-2	1277-1278	,	_	_	_	_
10-3	1279-1282	the	abstract[62]	new[62]	coref	10-9[64_62]
10-4	1283-1290	pathway	abstract[62]	new[62]	_	_
10-5	1291-1293	to	abstract[62]	new[62]	_	_
10-6	1294-1300	mental	abstract[62]|abstract[63]	new[62]|giv[63]	coref	11-39[86_63]
10-7	1301-1310	disorders	abstract[62]|abstract[63]	new[62]|giv[63]	_	_
10-8	1311-1313	is	_	_	_	_
10-9	1314-1315	a	abstract[64]	giv[64]	_	_
10-10	1316-1323	complex	abstract[64]	giv[64]	_	_
10-11	1324-1327	and	abstract[64]	giv[64]	_	_
10-12	1328-1339	interactive	abstract[64]	giv[64]	_	_
10-13	1340-1347	process	abstract[64]	giv[64]	_	_
10-14	1348-1349	,	_	_	_	_
10-15	1350-1353	and	_	_	_	_
10-16	1354-1367	over-reliance	_	_	_	_
10-17	1368-1370	on	_	_	_	_
10-18	1371-1381	individual	abstract[65]	giv[65]	_	_
10-19	1382-1391	treatment	abstract[65]	giv[65]	_	_
10-20	1392-1394	at	_	_	_	_
10-21	1395-1398	the	abstract[66]	new[66]	_	_
10-22	1399-1406	expense	abstract[66]	new[66]	_	_
10-23	1407-1409	of	abstract[66]	new[66]	_	_
10-24	1410-1417	broader	abstract[66]|abstract[67]	new[66]|new[67]	_	_
10-25	1418-1419	“	abstract[66]|abstract[67]	new[66]|new[67]	_	_
10-26	1420-1430	structural	abstract[66]|abstract[67]	new[66]|new[67]	_	_
10-27	1431-1441	prevention	abstract[66]|abstract[67]	new[66]|new[67]	_	_
10-28	1442-1443	”	abstract[66]|abstract[67]	new[66]|new[67]	_	_
10-29	1444-1454	approaches	_	_	_	_
10-30	1455-1458	has	_	_	_	_
10-31	1459-1466	further	_	_	_	_
10-32	1467-1475	hindered	_	_	_	_
10-33	1476-1479	the	abstract[68]	new[68]	_	_
10-34	1480-1490	successful	abstract[68]	new[68]	_	_
10-35	1491-1500	reduction	abstract[68]	new[68]	_	_
10-36	1501-1503	of	abstract[68]	new[68]	_	_
10-37	1504-1511	disease	abstract[68]|abstract|abstract[70]	new[68]|new|giv[70]	coref|coref	14-12|14-12
10-38	1512-1522	prevalence	abstract[68]|abstract[70]	new[68]|giv[70]	_	_
10-39	1523-1524	.	_	_	_	_

#Text=It was unfortunate that the WHO evidence review on mental health was hampered mainly by the broad outcome selection , which embraced different levels of severity , from health-related quality of life to clinical outcomes like depression or anxiety disorders .
11-1	1525-1527	It	abstract	new	cata	11-1[0_75]
11-2	1528-1531	was	_	_	_	_
11-3	1532-1543	unfortunate	_	_	_	_
11-4	1544-1548	that	abstract[75]	new[75]	_	_
11-5	1549-1552	the	abstract[73]|abstract[75]	new[73]|new[75]	coref	15-5[117_73]
11-6	1553-1556	WHO	abstract[73]|abstract[75]	new[73]|new[75]	_	_
11-7	1557-1565	evidence	abstract|abstract[73]|abstract[75]	giv|new[73]|new[75]	coref	14-3[108_0]
11-8	1566-1572	review	abstract[73]|abstract[75]	new[73]|new[75]	_	_
11-9	1573-1575	on	abstract[73]|abstract[75]	new[73]|new[75]	_	_
11-10	1576-1582	mental	abstract[73]|abstract[74]|abstract[75]	new[73]|giv[74]|new[75]	coref	13-15[0_74]
11-11	1583-1589	health	abstract[73]|abstract[74]|abstract[75]	new[73]|giv[74]|new[75]	_	_
11-12	1590-1593	was	abstract[75]	new[75]	_	_
11-13	1594-1602	hampered	abstract[75]	new[75]	_	_
11-14	1603-1609	mainly	abstract[75]	new[75]	_	_
11-15	1610-1612	by	_	_	_	_
11-16	1613-1616	the	abstract[77]	new[77]	_	_
11-17	1617-1622	broad	abstract[77]	new[77]	_	_
11-18	1623-1630	outcome	event|abstract[77]	new|new[77]	_	_
11-19	1631-1640	selection	abstract[77]	new[77]	_	_
11-20	1641-1642	,	_	_	_	_
11-21	1643-1648	which	_	_	_	_
11-22	1649-1657	embraced	_	_	_	_
11-23	1658-1667	different	abstract[78]	new[78]	_	_
11-24	1668-1674	levels	abstract[78]	new[78]	_	_
11-25	1675-1677	of	abstract[78]	new[78]	_	_
11-26	1678-1686	severity	abstract[78]|abstract	new[78]|new	_	_
11-27	1687-1688	,	_	_	_	_
11-28	1689-1693	from	_	_	_	_
11-29	1694-1708	health-related	abstract[80]	new[80]	coref	16-11[0_80]
11-30	1709-1716	quality	abstract[80]	new[80]	_	_
11-31	1717-1719	of	abstract[80]	new[80]	_	_
11-32	1720-1724	life	abstract[80]|abstract[81]	new[80]|giv[81]	_	_
11-33	1725-1727	to	abstract[80]|abstract[81]	new[80]|giv[81]	_	_
11-34	1728-1736	clinical	abstract[80]|abstract[81]|event[82]	new[80]|giv[81]|new[82]	coref	12-7[90_82]
11-35	1737-1745	outcomes	abstract[80]|abstract[81]|event[82]	new[80]|giv[81]|new[82]	_	_
11-36	1746-1750	like	abstract[80]|abstract[81]|event[82]	new[80]|giv[81]|new[82]	_	_
11-37	1751-1761	depression	abstract[80]|abstract[81]|event[82]|abstract|abstract[84]	new[80]|giv[81]|new[82]|giv|new[84]	coref|coref|coref|coref	15-32|15-32[126_84]|15-32|15-32[126_84]
11-38	1762-1764	or	abstract[80]|abstract[81]|event[82]|abstract[84]	new[80]|giv[81]|new[82]|new[84]	_	_
11-39	1765-1772	anxiety	abstract[80]|abstract[81]|event[82]|abstract[84]|abstract|abstract[86]	new[80]|giv[81]|new[82]|new[84]|giv|giv[86]	coref|coref|coref|coref	15-34[128_86]|18-13|15-34[128_86]|18-13
11-40	1773-1782	disorders	abstract[80]|abstract[81]|event[82]|abstract[84]|abstract[86]	new[80]|giv[81]|new[82]|new[84]|giv[86]	_	_
11-41	1783-1784	.	_	_	_	_

#Text=The small number of studies in the sub-section outcomes and the diverse measurement instruments used in the available studies ( symptom questionnaires , clinical diagnoses , psychotropic medication ) prevented the authors from conducting full meta-analyses .
12-1	1785-1788	The	quantity[87]	new[87]	_	_
12-2	1789-1794	small	quantity[87]	new[87]	_	_
12-3	1795-1801	number	quantity[87]	new[87]	_	_
12-4	1802-1804	of	quantity[87]	new[87]	_	_
12-5	1805-1812	studies	quantity[87]|event[88]	new[87]|new[88]	coref	12-17[93_88]
12-6	1813-1815	in	quantity[87]|event[88]	new[87]|new[88]	_	_
12-7	1816-1819	the	quantity[87]|event[88]|event[90]	new[87]|new[88]|giv[90]	coref	13-12[105_90]
12-8	1820-1831	sub-section	quantity[87]|event[88]|place|event[90]	new[87]|new[88]|new|giv[90]	_	_
12-9	1832-1840	outcomes	quantity[87]|event[88]|event[90]	new[87]|new[88]|giv[90]	_	_
12-10	1841-1844	and	quantity[87]|event[88]|event[90]	new[87]|new[88]|giv[90]	_	_
12-11	1845-1848	the	quantity[87]|event[88]|event[90]|abstract[92]	new[87]|new[88]|giv[90]|new[92]	_	_
12-12	1849-1856	diverse	quantity[87]|event[88]|event[90]|abstract[92]	new[87]|new[88]|giv[90]|new[92]	_	_
12-13	1857-1868	measurement	quantity[87]|event[88]|event[90]|abstract|abstract[92]	new[87]|new[88]|giv[90]|new|new[92]	_	_
12-14	1869-1880	instruments	quantity[87]|event[88]|event[90]|abstract[92]	new[87]|new[88]|giv[90]|new[92]	_	_
12-15	1881-1885	used	_	_	_	_
12-16	1886-1888	in	_	_	_	_
12-17	1889-1892	the	event[93]	giv[93]	coref	13-8[103_93]
12-18	1893-1902	available	event[93]	giv[93]	_	_
12-19	1903-1910	studies	event[93]	giv[93]	_	_
12-20	1911-1912	(	_	_	_	_
12-21	1913-1920	symptom	abstract|abstract[95]	new|new[95]	_	_
12-22	1921-1935	questionnaires	abstract[95]	new[95]	_	_
12-23	1936-1937	,	_	_	_	_
12-24	1938-1946	clinical	abstract[96]	new[96]	_	_
12-25	1947-1956	diagnoses	abstract[96]	new[96]	_	_
12-26	1957-1958	,	_	_	_	_
12-27	1959-1971	psychotropic	abstract|abstract[98]	new|new[98]	_	_
12-28	1972-1982	medication	abstract[98]	new[98]	_	_
12-29	1983-1984	)	_	_	_	_
12-30	1985-1994	prevented	_	_	_	_
12-31	1995-1998	the	person[99]	new[99]	_	_
12-32	1999-2006	authors	person[99]	new[99]	_	_
12-33	2007-2011	from	_	_	_	_
12-34	2012-2022	conducting	_	_	_	_
12-35	2023-2027	full	abstract[100]	new[100]	_	_
12-36	2028-2041	meta-analyses	abstract[100]	new[100]	_	_
12-37	2042-2043	.	_	_	_	_

#Text=Clark and Paunovic concluded that there were too few studies of clinically significant mental health outcomes , and studies of large samples were needed .
13-1	2044-2049	Clark	person	new	_	_
13-2	2050-2053	and	_	_	_	_
13-3	2054-2062	Paunovic	person	new	_	_
13-4	2063-2072	concluded	_	_	_	_
13-5	2073-2077	that	_	_	_	_
13-6	2078-2083	there	_	_	_	_
13-7	2084-2088	were	_	_	_	_
13-8	2089-2092	too	event[103]	giv[103]	_	_
13-9	2093-2096	few	event[103]	giv[103]	_	_
13-10	2097-2104	studies	event[103]	giv[103]	_	_
13-11	2105-2107	of	event[103]	giv[103]	_	_
13-12	2108-2118	clinically	event[103]|event[105]	giv[103]|giv[105]	coref	15-24[124_105]
13-13	2119-2130	significant	event[103]|event[105]	giv[103]|giv[105]	_	_
13-14	2131-2137	mental	event[103]|event[105]	giv[103]|giv[105]	_	_
13-15	2138-2144	health	event[103]|abstract|event[105]	giv[103]|giv|giv[105]	coref	15-7
13-16	2145-2153	outcomes	event[103]|event[105]	giv[103]|giv[105]	_	_
13-17	2154-2155	,	_	_	_	_
13-18	2156-2159	and	_	_	_	_
13-19	2160-2167	studies	event[106]	new[106]	coref	15-21[122_106]
13-20	2168-2170	of	event[106]	new[106]	_	_
13-21	2171-2176	large	event[106]|quantity[107]	new[106]|new[107]	_	_
13-22	2177-2184	samples	event[106]|quantity[107]	new[106]|new[107]	_	_
13-23	2185-2189	were	_	_	_	_
13-24	2190-2196	needed	_	_	_	_
13-25	2197-2198	.	_	_	_	_

#Text=However , quantitative evidence is a necessary requirement for burden of disease estimation and setting exposure guidelines .
14-1	2199-2206	However	_	_	_	_
14-2	2207-2208	,	_	_	_	_
14-3	2209-2221	quantitative	abstract[108]	giv[108]	coref	14-6[109_108]
14-4	2222-2230	evidence	abstract[108]	giv[108]	_	_
14-5	2231-2233	is	_	_	_	_
14-6	2234-2235	a	abstract[109]	giv[109]	coref	16-15[0_109]
14-7	2236-2245	necessary	abstract[109]	giv[109]	_	_
14-8	2246-2257	requirement	abstract[109]	giv[109]	_	_
14-9	2258-2261	for	abstract[109]	giv[109]	_	_
14-10	2262-2268	burden	abstract[109]|abstract[110]	giv[109]|giv[110]	_	_
14-11	2269-2271	of	abstract[109]|abstract[110]	giv[109]|giv[110]	_	_
14-12	2272-2279	disease	abstract[109]|abstract[110]|abstract|abstract[112]	giv[109]|giv[110]|giv|new[112]	_	_
14-13	2280-2290	estimation	abstract[109]|abstract[110]|abstract[112]	giv[109]|giv[110]|new[112]	_	_
14-14	2291-2294	and	_	_	_	_
14-15	2295-2302	setting	_	_	_	_
14-16	2303-2311	exposure	abstract|abstract[114]	new|new[114]	coref|coref	18-16[143_0]|18-16[143_0]
14-17	2312-2322	guidelines	abstract[114]	new[114]	_	_
14-18	2323-2324	.	_	_	_	_

#Text=In the meantime ( the mental health review included papers up to October 2015 ) , a sufficient number of new studies on more severe mental health outcomes , such as depression and other mental health disorders , were published .
15-1	2325-2327	In	_	_	_	_
15-2	2328-2331	the	time[115]	new[115]	_	_
15-3	2332-2340	meantime	time[115]	new[115]	_	_
15-4	2341-2342	(	_	_	_	_
15-5	2343-2346	the	abstract[117]	giv[117]	coref	17-10[137_117]
15-6	2347-2353	mental	abstract[117]	giv[117]	_	_
15-7	2354-2360	health	abstract|abstract[117]	giv|giv[117]	coref	15-27
15-8	2361-2367	review	abstract[117]	giv[117]	_	_
15-9	2368-2376	included	_	_	_	_
15-10	2377-2383	papers	object	new	_	_
15-11	2384-2386	up	_	_	_	_
15-12	2387-2389	to	_	_	_	_
15-13	2390-2397	October	time[119]	new[119]	_	_
15-14	2398-2402	2015	time[119]|time	new[119]|new	_	_
15-15	2403-2404	)	_	_	_	_
15-16	2405-2406	,	_	_	_	_
15-17	2407-2408	a	abstract[121]	new[121]	_	_
15-18	2409-2419	sufficient	abstract[121]	new[121]	_	_
15-19	2420-2426	number	abstract[121]	new[121]	_	_
15-20	2427-2429	of	abstract[121]	new[121]	_	_
15-21	2430-2433	new	abstract[121]|event[122]	new[121]|giv[122]	coref	16-1[129_122]
15-22	2434-2441	studies	abstract[121]|event[122]	new[121]|giv[122]	_	_
15-23	2442-2444	on	abstract[121]|event[122]	new[121]|giv[122]	_	_
15-24	2445-2449	more	abstract[121]|event[122]|event[124]	new[121]|giv[122]|giv[124]	coref	18-4[140_124]
15-25	2450-2456	severe	abstract[121]|event[122]|event[124]	new[121]|giv[122]|giv[124]	_	_
15-26	2457-2463	mental	abstract[121]|event[122]|event[124]	new[121]|giv[122]|giv[124]	_	_
15-27	2464-2470	health	abstract[121]|event[122]|abstract|event[124]	new[121]|giv[122]|giv|giv[124]	coref	15-36
15-28	2471-2479	outcomes	abstract[121]|event[122]|event[124]	new[121]|giv[122]|giv[124]	_	_
15-29	2480-2481	,	abstract[121]|event[122]|event[124]	new[121]|giv[122]|giv[124]	_	_
15-30	2482-2486	such	abstract[121]|event[122]|event[124]	new[121]|giv[122]|giv[124]	_	_
15-31	2487-2489	as	abstract[121]|event[122]|event[124]	new[121]|giv[122]|giv[124]	_	_
15-32	2490-2500	depression	abstract[121]|event[122]|event[124]|abstract|abstract[126]	new[121]|giv[122]|giv[124]|giv|giv[126]	coref|coref	18-11|18-11
15-33	2501-2504	and	abstract[121]|event[122]|event[124]|abstract[126]	new[121]|giv[122]|giv[124]|giv[126]	_	_
15-34	2505-2510	other	abstract[121]|event[122]|event[124]|abstract[126]|abstract[128]	new[121]|giv[122]|giv[124]|giv[126]|giv[128]	coref	19-33[162_128]
15-35	2511-2517	mental	abstract[121]|event[122]|event[124]|abstract[126]|abstract[128]	new[121]|giv[122]|giv[124]|giv[126]|giv[128]	_	_
15-36	2518-2524	health	abstract[121]|event[122]|event[124]|abstract[126]|abstract|abstract[128]	new[121]|giv[122]|giv[124]|giv[126]|giv|giv[128]	coref	19-15
15-37	2525-2534	disorders	abstract[121]|event[122]|event[124]|abstract[126]|abstract[128]	new[121]|giv[122]|giv[124]|giv[126]|giv[128]	_	_
15-38	2535-2536	,	_	_	_	_
15-39	2537-2541	were	_	_	_	_
15-40	2542-2551	published	_	_	_	_
15-41	2552-2553	.	_	_	_	_

#Text=A few studies were of longitudinal design and improved the quality aspect of the evidence base .
16-1	2554-2555	A	event[129]	giv[129]	coref	17-19[139_129]
16-2	2556-2559	few	event[129]	giv[129]	_	_
16-3	2560-2567	studies	event[129]	giv[129]	_	_
16-4	2568-2572	were	_	_	_	_
16-5	2573-2575	of	_	_	_	_
16-6	2576-2588	longitudinal	abstract[130]	new[130]	_	_
16-7	2589-2595	design	abstract[130]	new[130]	_	_
16-8	2596-2599	and	_	_	_	_
16-9	2600-2608	improved	_	_	_	_
16-10	2609-2612	the	abstract[132]	new[132]	_	_
16-11	2613-2620	quality	abstract|abstract[132]	giv|new[132]	_	_
16-12	2621-2627	aspect	abstract[132]	new[132]	_	_
16-13	2628-2630	of	abstract[132]	new[132]	_	_
16-14	2631-2634	the	abstract[132]|abstract[134]	new[132]|new[134]	ana	17-2[135_134]
16-15	2635-2643	evidence	abstract[132]|abstract|abstract[134]	new[132]|giv|new[134]	_	_
16-16	2644-2648	base	abstract[132]|abstract[134]	new[132]|new[134]	_	_
16-17	2649-2650	.	_	_	_	_

#Text=With that in mind , we aimed to supplement the WHO review by providing a formal meta-analysis with these additional studies .
17-1	2651-2655	With	_	_	_	_
17-2	2656-2660	that	abstract[135]	giv[135]	_	_
17-3	2661-2663	in	abstract[135]	giv[135]	_	_
17-4	2664-2668	mind	abstract[135]	giv[135]	_	_
17-5	2669-2670	,	_	_	_	_
17-6	2671-2673	we	person	acc	_	_
17-7	2674-2679	aimed	_	_	_	_
17-8	2680-2682	to	_	_	_	_
17-9	2683-2693	supplement	_	_	_	_
17-10	2694-2697	the	abstract[137]	giv[137]	_	_
17-11	2698-2701	WHO	abstract[137]	giv[137]	_	_
17-12	2702-2708	review	abstract[137]	giv[137]	_	_
17-13	2709-2711	by	_	_	_	_
17-14	2712-2721	providing	_	_	_	_
17-15	2722-2723	a	abstract[138]	new[138]	coref	19-1[150_138]
17-16	2724-2730	formal	abstract[138]	new[138]	_	_
17-17	2731-2744	meta-analysis	abstract[138]	new[138]	_	_
17-18	2745-2749	with	abstract[138]	new[138]	_	_
17-19	2750-2755	these	abstract[138]|event[139]	new[138]|giv[139]	_	_
17-20	2756-2766	additional	abstract[138]|event[139]	new[138]|giv[139]	_	_
17-21	2767-2774	studies	abstract[138]|event[139]	new[138]|giv[139]	_	_
17-22	2775-2776	.	_	_	_	_

#Text=By restricting to more confined clinical outcomes , such as depression and anxiety , and the exposure to residential road traffic noise ( as the most prevalent type of traffic noise exposure ) too many analysis subsets can be avoided .
18-1	2777-2779	By	_	_	_	_
18-2	2780-2791	restricting	_	_	_	_
18-3	2792-2794	to	_	_	_	_
18-4	2795-2799	more	event[140]	giv[140]	coref	19-24[158_140]
18-5	2800-2808	confined	event[140]	giv[140]	_	_
18-6	2809-2817	clinical	event[140]	giv[140]	_	_
18-7	2818-2826	outcomes	event[140]	giv[140]	_	_
18-8	2827-2828	,	event[140]	giv[140]	_	_
18-9	2829-2833	such	event[140]	giv[140]	_	_
18-10	2834-2836	as	event[140]	giv[140]	_	_
18-11	2837-2847	depression	event[140]|abstract	giv[140]|giv	_	_
18-12	2848-2851	and	event[140]	giv[140]	_	_
18-13	2852-2859	anxiety	event[140]|abstract	giv[140]|giv	_	_
18-14	2860-2861	,	event[140]	giv[140]	_	_
18-15	2862-2865	and	event[140]	giv[140]	_	_
18-16	2866-2869	the	event[140]|abstract[143]	giv[140]|giv[143]	_	_
18-17	2870-2878	exposure	event[140]|abstract[143]	giv[140]|giv[143]	_	_
18-18	2879-2881	to	event[140]|abstract[143]	giv[140]|giv[143]	_	_
18-19	2882-2893	residential	event[140]|abstract[143]|abstract[146]	giv[140]|giv[143]|giv[146]	coref	19-18[156_146]
18-20	2894-2898	road	event[140]|abstract[143]|object|abstract[146]	giv[140]|giv[143]|new|giv[146]	_	_
18-21	2899-2906	traffic	event[140]|abstract[143]|abstract|abstract[146]	giv[140]|giv[143]|new|giv[146]	coref	18-30
18-22	2907-2912	noise	event[140]|abstract[143]|abstract[146]	giv[140]|giv[143]|giv[146]	_	_
18-23	2913-2914	(	event[140]|abstract[143]|abstract[146]	giv[140]|giv[143]|giv[146]	_	_
18-24	2915-2917	as	event[140]|abstract[143]|abstract[146]	giv[140]|giv[143]|giv[146]	_	_
18-25	2918-2921	the	event[140]|abstract[143]|abstract[146]	giv[140]|giv[143]|giv[146]	_	_
18-26	2922-2926	most	event[140]|abstract[143]|abstract[146]	giv[140]|giv[143]|giv[146]	_	_
18-27	2927-2936	prevalent	event[140]|abstract[143]|abstract[146]	giv[140]|giv[143]|giv[146]	_	_
18-28	2937-2941	type	event[140]|abstract[143]|abstract[146]	giv[140]|giv[143]|giv[146]	_	_
18-29	2942-2944	of	event[140]|abstract[143]|abstract[146]	giv[140]|giv[143]|giv[146]	_	_
18-30	2945-2952	traffic	event[140]|abstract[143]|abstract[146]|abstract	giv[140]|giv[143]|giv[146]|giv	coref	19-18
18-31	2953-2958	noise	event[140]|abstract[143]|abstract[146]	giv[140]|giv[143]|giv[146]	_	_
18-32	2959-2967	exposure	event[140]|abstract[143]|abstract[146]	giv[140]|giv[143]|giv[146]	_	_
18-33	2968-2969	)	event[140]|abstract[143]|abstract[146]	giv[140]|giv[143]|giv[146]	_	_
18-34	2970-2973	too	abstract[149]	new[149]	_	_
18-35	2974-2978	many	abstract[149]	new[149]	_	_
18-36	2979-2987	analysis	abstract|abstract[149]	new|new[149]	_	_
18-37	2988-2995	subsets	abstract[149]	new[149]	_	_
18-38	2996-2999	can	_	_	_	_
18-39	3000-3002	be	_	_	_	_
18-40	3003-3010	avoided	_	_	_	_
18-41	3011-3012	.	_	_	_	_

#Text=The updated meta-analysis should add to the growing collection of up-to-date systematic reviews on health effects of traffic noise ( e. g. , birth outcomes , cardiovascular and metabolic disease , and behavioral/emotional disorders in youth ) .
19-1	3013-3016	The	abstract[150]	giv[150]	_	_
19-2	3017-3024	updated	abstract[150]	giv[150]	_	_
19-3	3025-3038	meta-analysis	abstract[150]	giv[150]	_	_
19-4	3039-3045	should	_	_	_	_
19-5	3046-3049	add	_	_	_	_
19-6	3050-3052	to	_	_	_	_
19-7	3053-3056	the	abstract[151]	new[151]	_	_
19-8	3057-3064	growing	abstract[151]	new[151]	_	_
19-9	3065-3075	collection	abstract[151]	new[151]	_	_
19-10	3076-3078	of	abstract[151]	new[151]	_	_
19-11	3079-3089	up-to-date	abstract[151]|abstract[152]	new[151]|giv[152]	_	_
19-12	3090-3100	systematic	abstract[151]|abstract[152]	new[151]|giv[152]	_	_
19-13	3101-3108	reviews	abstract[151]|abstract[152]	new[151]|giv[152]	_	_
19-14	3109-3111	on	abstract[151]|abstract[152]	new[151]|giv[152]	_	_
19-15	3112-3118	health	abstract[151]|abstract[152]|abstract|abstract[154]	new[151]|giv[152]|giv|new[154]	_	_
19-16	3119-3126	effects	abstract[151]|abstract[152]|abstract[154]	new[151]|giv[152]|new[154]	_	_
19-17	3127-3129	of	abstract[151]|abstract[152]|abstract[154]	new[151]|giv[152]|new[154]	_	_
19-18	3130-3137	traffic	abstract[151]|abstract[152]|abstract[154]|abstract|abstract[156]	new[151]|giv[152]|new[154]|giv|giv[156]	appos|appos	19-27[0_156]|19-27[0_156]
19-19	3138-3143	noise	abstract[151]|abstract[152]|abstract[154]|abstract[156]	new[151]|giv[152]|new[154]|giv[156]	_	_
19-20	3144-3145	(	_	_	_	_
19-21	3146-3148	e.	_	_	_	_
19-22	3149-3151	g.	_	_	_	_
19-23	3152-3153	,	_	_	_	_
19-24	3154-3159	birth	event|event[158]	new|giv[158]	_	_
19-25	3160-3168	outcomes	event[158]	giv[158]	_	_
19-26	3169-3170	,	_	_	_	_
19-27	3171-3185	cardiovascular	abstract	giv	appos	19-29[161_0]
19-28	3186-3189	and	_	_	_	_
19-29	3190-3199	metabolic	person|abstract[161]	new|giv[161]	_	_
19-30	3200-3207	disease	abstract[161]	giv[161]	_	_
19-31	3208-3209	,	_	_	_	_
19-32	3210-3213	and	_	_	_	_
19-33	3214-3234	behavioral/emotional	abstract[162]	giv[162]	_	_
19-34	3235-3244	disorders	abstract[162]	giv[162]	_	_
19-35	3245-3247	in	abstract[162]	giv[162]	_	_
19-36	3248-3253	youth	abstract[162]|person	giv[162]|new	_	_
19-37	3254-3255	)	_	_	_	_
19-38	3256-3257	.	_	_	_	_
